Mezzasalma Advisors LLC Has $4.86 Million Position in Eli Lilly and Company (NYSE:LLY)

Mezzasalma Advisors LLC boosted its position in shares of Eli Lilly and Company (NYSE:LLY) by 110.3% in the first quarter, Holdings Channel reports. The firm owned 6,243 shares of the company’s stock after purchasing an additional 3,275 shares during the period. Eli Lilly and Company accounts for 2.3% of Mezzasalma Advisors LLC’s investment portfolio, making the stock its 12th biggest holding. Mezzasalma Advisors LLC’s holdings in Eli Lilly and Company were worth $4,857,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. increased its position in shares of Eli Lilly and Company by 0.9% during the third quarter. Vanguard Group Inc. now owns 70,575,602 shares of the company’s stock worth $37,908,273,000 after acquiring an additional 659,838 shares in the last quarter. Capital World Investors increased its position in shares of Eli Lilly and Company by 0.3% during the fourth quarter. Capital World Investors now owns 26,949,773 shares of the company’s stock worth $15,709,466,000 after acquiring an additional 89,720 shares in the last quarter. Morgan Stanley increased its position in shares of Eli Lilly and Company by 0.7% during the third quarter. Morgan Stanley now owns 12,545,572 shares of the company’s stock worth $6,738,605,000 after acquiring an additional 83,915 shares in the last quarter. Norges Bank bought a new stake in shares of Eli Lilly and Company during the fourth quarter worth $5,992,890,000. Finally, Capital Research Global Investors increased its position in shares of Eli Lilly and Company by 4.5% during the fourth quarter. Capital Research Global Investors now owns 7,577,592 shares of the company’s stock worth $4,417,120,000 after acquiring an additional 325,342 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Insider Transactions at Eli Lilly and Company

In related news, major shareholder Lilly Endowment Inc sold 8,848 shares of the firm’s stock in a transaction dated Wednesday, July 3rd. The shares were sold at an average price of $915.31, for a total transaction of $8,098,662.88. Following the transaction, the insider now directly owns 97,299,772 shares of the company’s stock, valued at $89,059,454,309.32. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In related news, major shareholder Lilly Endowment Inc sold 8,848 shares of the firm’s stock in a transaction dated Wednesday, July 3rd. The shares were sold at an average price of $915.31, for a total transaction of $8,098,662.88. Following the transaction, the insider now directly owns 97,299,772 shares of the company’s stock, valued at $89,059,454,309.32. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Johna Norton sold 7,056 shares of the firm’s stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $819.38, for a total transaction of $5,781,545.28. Following the transaction, the executive vice president now directly owns 25,428 shares in the company, valued at $20,835,194.64. The disclosure for this sale can be found here. In the last 90 days, insiders sold 858,742 shares of company stock worth $735,573,781. 0.13% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the stock. Argus increased their price objective on shares of Eli Lilly and Company from $770.00 to $840.00 and gave the stock a “buy” rating in a research report on Tuesday, May 14th. Bank of America reissued a “buy” rating and set a $1,000.00 price objective on shares of Eli Lilly and Company in a research report on Monday, June 24th. TheStreet raised shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a research report on Friday, March 8th. The Goldman Sachs Group increased their target price on shares of Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a report on Thursday, April 11th. Finally, Jefferies Financial Group increased their target price on shares of Eli Lilly and Company from $994.00 to $1,015.00 and gave the stock a “buy” rating in a report on Monday, June 24th. Three investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to data from MarketBeat, Eli Lilly and Company presently has an average rating of “Moderate Buy” and a consensus target price of $812.72.

Eli Lilly and Company Stock Performance

LLY stock traded down $8.61 during trading hours on Thursday, reaching $898.10. The stock had a trading volume of 3,078,367 shares, compared to its average volume of 2,667,176. The stock has a market capitalization of $853.56 billion, a PE ratio of 132.27, a price-to-earnings-growth ratio of 1.98 and a beta of 0.41. The company has a debt-to-equity ratio of 1.90, a current ratio of 1.35 and a quick ratio of 1.03. The stock has a 50-day simple moving average of $824.60 and a 200 day simple moving average of $746.69. Eli Lilly and Company has a fifty-two week low of $434.34 and a fifty-two week high of $918.50.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Monday, May 6th. The company reported $2.58 EPS for the quarter, beating analysts’ consensus estimates of $2.53 by $0.05. The firm had revenue of $8.77 billion during the quarter, compared to analysts’ expectations of $8.94 billion. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The company’s revenue for the quarter was up 26.0% compared to the same quarter last year. During the same quarter last year, the company posted $1.62 earnings per share. Analysts predict that Eli Lilly and Company will post 13.76 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Thursday, August 15th will be paid a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.58%. The ex-dividend date is Thursday, August 15th. Eli Lilly and Company’s dividend payout ratio is presently 76.58%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.